News Sentiment

ARTV sentiment intelligence

Artiva Biotherapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 69 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.64 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 8

high-authority source matches

Trend context Trend active

+0.3% over one week, +12.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Ra Capital Management funds buy $194k in Artiva Biotherapeutics stock By Investing.com

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction 0.3% Price digesting
Trend fit Trend active 12.9% over four weeks
Fair value 49.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 38
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 7
GlobeNewswire 6
TradingKey 4
Investing.com 3
Quiver Quantitative 3
MT Newswires 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 45
Earnings 19
Deals and strategy 3
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 69
Investing.com South Africa Direct company coverage

Ra Capital Management funds buy $194k in Artiva Biotherapeutics stock By Investing.com

RA Capital Management funds recently acquired an additional $194,039 worth of Artiva Biotherapeutics (NASDAQ:ARTV) common stock over two days, increasing their already significant stake. These purchases involved shares bought at prices ranging from $8.94 to $8.97, even as Investi

Tone
Positive 67/100
Event
Deals and strategy
Published
15 Jul 2026 00:12
Source
Investing.com South Africa
Market source Direct company coverage

Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?

Artiva Biotherapeutics, Inc. (ARTV) is significantly outperforming the Medical sector and its specific industry (Medical - Biomedical and Genetics) this year, with a year-to-date return of 121% compared to the sector's 2.8% and the industry's 7.4%. The company holds a Zacks Rank

Tone
Positive 75/100
Event
Market update
Published
08 Jul 2026 08:40
Source
Market source
Investing.com Nigeria Direct company coverage

Form 4 Artiva Biotherapeutics Inc For: 29 June By Investing.com

This article reports on a Form 4 filing for Artiva Biotherapeutics Inc (ARTV) for June 29, 2026. Form 4 filings typically disclose transactions by corporate insiders. The article provides the date of the filing and mentions the company's stock symbol and current trading performan

Tone
Negative 41/100
Event
Market update
Published
30 Jun 2026 08:42
Source
Investing.com Nigeria
Investing.com Direct company coverage

Ra capital funds buy $292k Artiva Biotherapeutics stock in late June

Investment funds associated with RA Capital Management, L.P. recently purchased approximately $292,126 worth of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) stock. This comes as Artiva's shares have surged over 554% in the last year, and the company has received a Regenerative Medi

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 21:42
Source
Investing.com
marketscreener.com Direct company coverage

Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Index

Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) has been added to the Russell 2000 Index, as well as several related Russell indices including the Russell 2500 Growth, Russell 2000 Value, and Russell 3000 Index. This inclusion marks a significant milestone for the clinical-stage bi

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 17:52
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Value Benchmark

Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) has been added to the Russell 2000 Value Benchmark. The company is a clinical-stage biotechnology firm specializing in natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Its lead product candidate, AlloNK, i

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 15:39
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 3000E Growth Benchmark

Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) has been added to the Russell 3000E Growth Benchmark. This move signifies recognition within a broad market index, suggesting increased visibility and potential for investment. The company specializes in developing clinical-stage, nat

Tone
Positive 74/100
Event
Market update
Published
29 Jun 2026 08:39
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Growth Benchmark

Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV), a clinical-stage biotechnology company, has been added to the Russell 2000 Growth Benchmark index. This inclusion highlights the company's focus on developing NK cell-based therapies for autoimmune diseases and cancers. The article a

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 07:33
Source
marketscreener.com
TradingView Direct company coverage

Price to sales forward of Artiva Biotherapeutics, Inc. – NASDAQ:ARTV

This article provides financial information for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or an incomplete data point from a financial charting platform like TradingView, with no further details

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 20:11
Source
TradingView
TradingView Direct company coverage

Price to book forward of Artiva Biotherapeutics, Inc. – NASDAQ:ARTV

The article provides a title related to the "Price to book forward" for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) and lists various financial and market data services and tools available on the TradingView platform. However, the body of the article appears to primarily consist

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 15:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Artiva Biotherapeutics, Inc. – NASDAQ:ARTV

This page displays the enterprise value to EBITDA forward for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV). It presents financial data, market information, and related company details. The content is primarily a data presentation from TradingView, including a historical overview,

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 23:41
Source
TradingView
Market source Direct company coverage

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Artiva Biotherapeutics announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. Management will host a fireside chat on June 30, 2026, to discuss the company's clinical-stage cell therapies for autoimmune diseases, including their lead progra

Tone
Positive 63/100
Event
Market update
Published
26 Jun 2026 22:10
Source
Market source
TradingView Direct company coverage

ARTV Forecast — Price Target — Prediction for 2027

This article provides a detailed forecast for Artiva Biotherapeutics, Inc. (ARTV) stock, including analyst price targets, historical performance, earnings information, and financial data. It highlights that analysts have a maximum price estimate of $41.00 and a minimum of $23.00

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 18:41
Source
TradingView
TradingView Direct company coverage

Artiva Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:ARTV)

This article provides a detailed financial overview and analyst estimates for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV). It covers the company's financial performance, stock price movements, future forecasts, and key metrics such as market capitalization and earnings reports. T

Tone
Negative 39/100
Event
Earnings
Published
25 Jun 2026 18:41
Source
TradingView
TradingKey Direct company coverage

Artiva Biotherapeutics Inc (ARTV) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Artiva Biotherapeutics Inc (ARTV), which currently holds a weak financial score of 5.40, ranking low within the Biotechnology & Medical Research industry. Key financial metrics related to profitability, operational efficiency, and gro

Tone
Negative 31/100
Event
Market update
Published
24 Jun 2026 06:11
Source
TradingKey
GuruFocus Direct company coverage

RA CAPITAL MANAGEMENT, L.P. Increases Stake in Artiva Biotherape

RA CAPITAL MANAGEMENT, L.P. has significantly increased its stake in Artiva Biotherapeutics Inc. by acquiring an additional 1,434,155 shares. This transaction, executed on June 11, 2026, at $8 per share, brings their total holdings to 17,811,623 shares, representing 36.60% of Art

Tone
Positive 63/100
Event
Deals and strategy
Published
20 Jun 2026 01:10
Source
GuruFocus
TradingKey Direct company coverage

Artiva Biotherapeutics Inc (ARTV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

Artiva Biotherapeutics Inc (ARTV) has a current price momentum score of 8.92, ranking 67th in the Biotechnology & Medical Research industry. The stock is trading between a resistance level of $11.40 and a support level of $7.53, suggesting it's suitable for range-bound swing trad

Tone
Positive 63/100
Event
Market update
Published
18 Jun 2026 09:39
Source
TradingKey
TradingKey Direct company coverage

Artiva Biotherapeutics Inc (ARTV) Earnings Forecast: Future EPS & Revenue Growth Estimates

Artiva Biotherapeutics Inc (ARTV) has an earnings forecast score of 8.67, ranking 71 out of 388 in its industry, with an average analyst price target of $18.00. Six analysts recommend a "Buy" for ARTV, with a high target of $23.00 and a low of $10.00. The company's previous quart

Tone
Positive 66/100
Event
Earnings
Published
18 Jun 2026 08:39
Source
TradingKey
TradingKey Direct company coverage

Artiva Biotherapeutics Inc (ARTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Artiva Biotherapeutics Inc (ARTV), though it notes that relevant data for business segments and regional profit contribution has not yet been disclosed by the company. It briefly shows the stock's price, market cap, an

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 01:10
Source
TradingKey
Investing.com Direct company coverage

Ra capital acquires $4.6m in Artiva Biotherapeutics shares

RA Capital Healthcare Fund, L.P. recently acquired 531,326 shares of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) for approximately $4.6 million through three transactions between June 12 and June 16, 2026. This buying activity occurred as ARTV shares surged 341% over the past yea

Tone
Positive 66/100
Event
Market update
Published
17 Jun 2026 16:10
Source
Investing.com
Moomoo Direct company coverage

Artiva Biotherapeutics(ARTV.US) 10% Shareholder Buys US$4.6 Million in Common Stock

A 10% shareholder of Artiva Biotherapeutics (ARTV.US) recently purchased common stock worth approximately US$4.6 million. This significant insider transaction indicates increased confidence from a major stakeholder in the company's future prospects. Such large investments by key

Tone
Positive 72/100
Event
Market update
Published
16 Jun 2026 22:10
Source
Moomoo
Investing.com Australia Direct company coverage

Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock By Investing.com

RA Capital Management and its affiliated funds have acquired approximately $7.65 million worth of Artiva Biotherapeutics (NASDAQ: ARTV) common stock across several transactions between June 9 and June 11, 2026. These purchases increased the funds' indirect holdings, coinciding wi

Tone
Positive 71/100
Event
Market update
Published
12 Jun 2026 13:40
Source
Investing.com Australia
Investing.com Direct company coverage

Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock

RA Capital Management and its affiliated funds have acquired approximately $7.65 million worth of Artiva Biotherapeutics (NASDAQ: ARTV) common stock between June 9 and June 11, 2026. These purchases increase RA Capital Healthcare Fund's indirect holdings to over 16 million shares

Tone
Positive 72/100
Event
Market update
Published
12 Jun 2026 13:38
Source
Investing.com
RTTNews Direct company coverage

Artiva: Targeting A New Benchmark In Refractory Rheumatoid Arthritis With AlloNK

Artiva Biotherapeutics Inc. (ARTV) shares have dropped significantly from their 52-week high, currently trading around $8. The biotechnology company is developing AlloNK, a deep B-cell-depleting therapy, for patients with refractory rheumatoid arthritis who have not responded to

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 10:10
Source
RTTNews